141 related articles for article (PubMed ID: 38104031)
21. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
[TBL] [Abstract][Full Text] [Related]
23. Translocation renal cell carcinomas in adults: a single-institution experience.
Zhong M; De Angelo P; Osborne L; Paniz-Mondolfi AE; Geller M; Yang Y; Linehan WM; Merino MJ; Cordon-Cardo C; Cai D
Am J Surg Pathol; 2012 May; 36(5):654-62. PubMed ID: 22446944
[TBL] [Abstract][Full Text] [Related]
24. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
25. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
26. Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern.
Williamson SR; Eble JN; Palanisamy N
Hum Pathol; 2017 Apr; 62():175-179. PubMed ID: 27864122
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome.
Mendel L; Ambrosetti D; Bodokh Y; Ngo-Mai M; Durand M; Simbsler-Michel C; Delhorbe M; Amiel J; Pedeutour F
Genes Chromosomes Cancer; 2018 Mar; 57(3):99-113. PubMed ID: 29127730
[TBL] [Abstract][Full Text] [Related]
28. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
[TBL] [Abstract][Full Text] [Related]
29. VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
Caliò A; Brunelli M; Segala D; Pedron S; Doglioni C; Argani P; Martignoni G
Mod Pathol; 2019 Feb; 32(2):258-268. PubMed ID: 30206412
[TBL] [Abstract][Full Text] [Related]
30. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
31. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.
Gupta S; Johnson SH; Vasmatzis G; Porath B; Rustin JG; Rao P; Costello BA; Leibovich BC; Thompson RH; Cheville JC; Sukov WR
Mod Pathol; 2017 Jul; 30(7):998-1012. PubMed ID: 28338654
[TBL] [Abstract][Full Text] [Related]
32. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
Caliò A; Brunelli M; Segala D; Pedron S; Tardanico R; Remo A; Gobbo S; Meneghelli E; Doglioni C; Hes O; Zampini C; Argani P; Martignoni G
Mod Pathol; 2018 Mar; 31(3):474-487. PubMed ID: 29052596
[TBL] [Abstract][Full Text] [Related]
33. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
[TBL] [Abstract][Full Text] [Related]
34. Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
Liu N; Wang Z; Gan W; Xiong L; Miao B; Chen X; Guo H; Li D
PLoS One; 2016; 11(11):e0166897. PubMed ID: 27893792
[TBL] [Abstract][Full Text] [Related]
35. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
[TBL] [Abstract][Full Text] [Related]
36. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
[TBL] [Abstract][Full Text] [Related]
37. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
Geller JI; Argani P; Adeniran A; Hampton E; De Marzo A; Hicks J; Collins MH
Cancer; 2008 Apr; 112(7):1607-16. PubMed ID: 18278810
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
Akgul M; Williamson SR; Ertoy D; Argani P; Gupta S; Caliò A; Reuter V; Tickoo S; Al-Ahmadie HA; Netto GJ; Hes O; Hirsch MS; Delahunt B; Mehra R; Skala S; Osunkoya AO; Harik L; Rao P; Sangoi AR; Nourieh M; Zynger DL; Smith SC; Nazeer T; Gumuskaya B; Kulac I; Khani F; Tretiakova MS; Vakar-Lopez F; Barkan G; Molinié V; Verkarre V; Rao Q; Kis L; Panizo A; Farzaneh T; Magers MJ; Sanfrancesco J; Perrino C; Gondim D; Araneta R; So JS; Ro JY; Wasco M; Hameed O; Lopez-Beltran A; Samaratunga H; Wobker SE; Melamed J; Cheng L; Idrees MT
J Clin Pathol; 2021 May; 74(5):291-299. PubMed ID: 33514585
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of key cell cycle regulators in renal cell carcinoma associated with Xp11.2 translocation.
Barroca H; Castedo S; Vieira J; Teixeira M; Müller-Höcker J
Pathol Res Pract; 2009; 205(7):466-72. PubMed ID: 19246164
[TBL] [Abstract][Full Text] [Related]
40. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]